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SHP-1 protein isoformsWe identiﬁed 7 SHP-1 (PTPN6) transcripts using epithelial cancer-derived cell lines. Four were shown to utilize the
epithelial promoter 1 to transcribe a full-length, a partial (exon 3) or complete (exons 3 & 4) deletion of the N-SH2
domain, and also a non-coding transcript having a stop codon caused by a frame shift due to intron 2 reten-
tion. Three additional transcripts were shown to utilize the hematopoietic promoter 2 to transcribe a full-length, a
partial (exon 3) deletion of the N-SH2 domain and a non-coding transcript with intron 2 retention. We show that
endogenous proteins corresponding to the open-reading-frame (ORF) transcripts are produced. Using GST-fusion
proteins we show that each product of the ORF SHP-1 transcripts has phosphatase activity and isoforms with an
N-SH2 deletion have increased phosphatase activity and novel protein–protein interactions. This study is the ﬁrst
to document utilization of promoter 2 by SHP-1 transcripts and a noncoding transcript in human epithelial cells.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
The intricate balance of phosphotyrosine residues on proteins is
controlled by the opposing actions of protein tyrosine kinases (PTK)
and protein tyrosine phosphatases (PTP) [1–5]. Perturbation of PTP
signaling can lead to abnormal accumulations of phosphorylated pro-
teinswhich candisrupt normal cell proliferation, differentiation, growth,
and adhesion.
SHP-1 (also designated as SHPTP-1, SHP, HCP and PTP1C, PTPN6) is a
68 kDa cytosolic PTP predominantly expressed in hematopoietic and
epithelial cells [6–8]. The human SHP-1 gene is located on chromosome
12p13 [9,10] and consists of 17 exons and 16 introns, spanning 17 kb of
DNA (6). SHP-1 contains two tandem src-homology 2 (SH2) domains,
three potential SH3-bindingmotifs (PxxP) for binding, a catalytic phos-
phatase domain and a C-terminal tail with two sites for tyrosine
phosphorylation [11–15]. In physiological conditions SHP-1 engages
in auto-inhibition due to intramolecular interaction between its N-
terminus SH2 (N-SH2) domain and its C-terminal tail [5,16]. N-
terminal deletion of SHP-1 can result in excessive phosphatase activityassert that there are no ﬁnancial
icine, University of Toronto, 67
ghts reserved.[17], which can disrupt normal signaling pathways and may contribute
to tumorigenesis [18].
Two promoters have been reported for SHP-1: promoter 1 (P1)
or epithelial promoter (EP) which directs the transcription of exon
1 encoding the amino acid sequence, Methionine–Leucine–Serine–
Arginine–Glycine (MLSRG) and promoter 2 (P2) or hematopoietic
promoter (HP) which initiates the transcription of exon 2 encoding
the amino sequence, Methionine–Valine–Arginine (MVR) at the N-
terminus [6]. P1 has been suggested to be predominantly expressed
by epithelial cells whereas P2 is active in cells of the hematopoietic
lineage [6]. The exclusivity of these promoters, however has recently
been questioned [8].
Loss of SHP-1 leads to extensive hematopoietic disruptions in mice
including aberrant expansion and tissue accumulation of myeloid/
monocytic cells that results in death in motheaten (me/me) mice that
do not express SHP-1 at about 2-3 weeks or in motheaten-viable
(mev/mev) mice that express aberrant SHP-1, at 9-12 weeks [17–19].
An absence of SHP-1 expression has been observed in the development
of several human cancers including B and T cell lymphoma and T-cell
chronic lymphocyte leukemia (TCLL) and chronicmyelogenous leukemia
(CML) [18,20,21]. In addition, growth of CML ormalignant hematopoietic
cell lines can be suppressedwith introduction ofwild-type SHP-1 [18,20–
25]; these ﬁndings implicate SHP-1 as a potential tumor suppressor
and as a critical regulator of a broad range of hematopoietic cell func-
tions [20–25]. The role of SHP-1 in epithelial cells, however, and its
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hanced expression of SHP-1 has been documented in several epithe-
lial cancers, including prostate [26], breast [27] and ovarian cancers
[7,8]. The differences in SHP-1 expression may be an outcome of
the cell type versus its role in cancer progression and development
[25-27]. However, recent work has shown that SHP-1 is a negative
regulator of proliferation in malignant breast adenocarcinoma using
its N-terminal domain [28]. In prostate cancer, proper binding between
SHP-1 and somatostatin is required to negatively regulate cancer growth
[26].
In this study, we examined SHP-1 transcripts in different human
colon, breast and other epithelial cancer-derived cells to obtain a better
understanding of the possible role of SHP-1 in these cancers. We show
for the ﬁrst time P1 and P2 utilization in human epithelial cells. In
addition to the three transcripts previously reported [6]; we identiﬁed
an additional 4 transcripts, 2 having open reading frames and 2 noncod-
ing transcripts having a frame shift due to retention of an intron, thatwas
previously reported for hematopoietic SHP-1 [18]. This study is also the
ﬁrst to show endogenous protein expression representing the variant
SHP-1mRNAaswell as protein bindingpatterns of variant SHP-1proteins
encoded by alternatively-spliced transcripts. SHP-1 alternative splicing
and production of protein isoforms may have functional consequences
and subsequent biological impact in human epithelial cells.
2. Results and discussion
2.1. Identiﬁcation of multiple SHP-1 transcripts in epithelial cancer cells
We have re-examined the SHP-1 transcripts present in epithelial
cancer-derived cell lines. Previously, it was thought that the selective
expression of SHP-1 is governed by two speciﬁc promoter regions: pro-
moter 1 (P1) or epithelial promoter (EP) which is located upstreamFig. 1. Schematic diagram of N-terminal region of genomic SHP-1. Shows the positions of intron
by RT-PCR in various human epithelial cancer cell lines. The sizes of the corresponding PCR p
translate a full-length 68 kDa protein and truncated proteins of 63 kDa and 56 kDa, with partifrom exon 1 (exon 1a in ref. [29]) or by promoter 2 (P2) also known
as hematopoietic promoter (HP) situated upstream from exon 2 (exon
1b in ref. [29]) (Fig. 1). In contrast to a previous report (Banville et al.
[6]) that only promoter 1 is used in epithelial cancer cells, in our study
we identiﬁed SHP-1mRNA transcripts containing exon 1 and exon 2, in-
dicating that both promoters are utilized in epithelial cells (Fig. 2A). Fur-
thermore, we have characterized 4 additional, novel SHP-1 transcripts
(Figs. 1, 2B and C) which add to the previous studies conducted by
Banville et al. [6] who showed 3 SHP-1 transcripts using A431 cancer-
derived cells. In our studies, we used multiple cancer-derived cell
lines, including frombreast and colon cancers, and forward primers spe-
ciﬁcally designed for P1 or P2 promoter use. Under the control of P1, we
identiﬁed a full-length SHP-1 transcript and transcripts lacking either
exon 3 or both exons 3 and 4, which correspond to those found by
Banville et al. [6] (Fig. 2B). In addition to A431, we identiﬁed novel
SHP-1 transcripts in epithelial cancer cell lines not previously examined,
including colon cancer cell line Colo 205, benign breast-derived cell line
MCF-10A, and the breast cancer cell lines MCF-7, MB231, and SK-BR-3
(Fig. 2). Our results also indicated that multiple transcripts were differ-
entially expressed, depending on the cancer cell used (Fig. 2B). Under
the control of P2, we found SHP-1 transcripts corresponding to wild-
type and exon 3 deleted SHP-1 mRNA (Fig. 2). We did not ﬁnd a tran-
script lacking both exons 3 and 4 under the control of the P2 promoter.
Again, as with P1 promoter, we found differential expression of tran-
scripts under the control of P2 in different cancer-derived cells
(Fig. 2). These are the ﬁrst SHP-1 transcripts and SHP-1 variants identi-
ﬁed that speciﬁcally use promoter 2 in human epithelial cells. Addition-
ally, we have identiﬁed two novel SHP-1 transcripts, one using the
epithelial promoter and one using the hematopoietic promoter, that re-
tain intron 2 (Fig. 2; largest bp product; 685 bp using P1 and 710 bp
using P2), resulting in a non-coding transcript, similar to those we
found earlier in KiT 225 leukemia-derived and the HuT 78 lymphoma-s and exons 1 thru 6 and representations of themultiple SHP-1mRNA transcripts detected
roducts in base pairs (bp) are indicated. These transcripts have open reading frames and
al and complete deletion of the SHP-1 N-SH2 domain, respectively.
Fig. 2. SHP-1 mRNA from various epithelial cancer cells. Using RT-PCR, products are shown for: (A) SHP-1 transcripts from SK-BR-3 human breast cancer cells, using forward primers
speciﬁc for either the epithelial promoter 1 (EF) or the hematopoietic promoter 2 (HF) and the common reverse primer (3R). (B) SHP-1 transcripts from various human epithelial cancer
cell lines using epithelial promoter (lanes 1–5) or hematopoietic promoter (lanes 7–11). Negative control is water (lane 6). (C) Representative of PCR products from transcripts generated
fromhematopoietic promoter (left) or from epithelial promoter (right), thatwere cloned into pGEM-T Easy vectors, isolated and sequenced. (D) SHP-1 proteinswere immunoprecipitated
from lysates made from platelets (control) or MCF-7 and SK-BR-3 cancer cell lines (108 cells). Immune complexes were run on 10% SDS-PAGE under non-reducing conditions. Arrows
indicate proteins of 68 kDa, 63 kDa and 56 kDa, relative to molecular weight standards.
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promoters 1 and 2, and intron 2 retention (highlighting the similarity be-
tween SHP-1mRNA expression in human epithelial and hematopoietic
cells). Furthermore, our ﬁnding of an epithelial SHP-1 transcript
lacking exons 3 and 4 support results reported by Martin et al. where
an analogous SHP-1 transcript using promoter 1 was identiﬁed [17,23].
Althoughwe conﬁrm the original work by Banville et al. [6], we have
discovered additional and novel transcripts not previously reported. As
we did not conﬁrm the presence of polyA in our transcripts, it is possible
that the novel transcripts are artifacts due to the use of transformed
cells. However, we identiﬁed these transcripts in a number of differentcancer cell lines, used promoter-speciﬁc primers, cloned and sequenced
a number of the fragments and found consistency in the results from cell
line to cell line making it unlikely that these were artifacts.
2.2. Endogenous proteins corresponding to SHP-1 mRNA found in cancer
cell lines
We next examined whether endogenous proteins are produced
from the three SHP-1 transcripts which have open reading frames
(ORFs). Although Banville et al. [6] stated without showing any results,
that variant proteins could not be identiﬁed, they did not provide a
494 S. Evren et al. / Genomics 102 (2013) 491–499detailed method or results with controls. They apparently used only
Western blot of cell lysate and did not use immunoprecipitation of
SHP-1 followed by Western blotting as was done in our study. In addi-
tion, these authors state that they used a polyclonal anti-SHP-1 in
their protein studies but did not indicate where this antibody was
from or any details of this polyclonal anti-SHP-1. For both immunopre-
cipitation andWestern immunoblotting, we used a speciﬁc monoclonal
anti-SHP-1 directed to the C-terminal portion of the molecule allowing
for detection of SHP-1 proteins truncated in their N-terminal region.
Using our approach, wewere able to identify endogenously produced
proteins of 68 kDa using MCF-7 and SK-BR-3 breast cancer-derived
cell lines but also proteins of 63 kDa (MCF-7 and SK-BR-3) and
56 kDa (SK-BR-3) that correspond to the predicted molecular size
of the SHP-1 transcript lacking exon 3 of the N-SH2 domain and the
truncated SHP-1 transcript lacking both exons 3 and 4 (Figs. 1 and 2D).
The use of non-reducing conditions allowed the clear identiﬁcation of
the 63 kDa and 56 kDa proteins without interference from the heavy
chain of the immunoprecipitating antibody (Fig. 2D). Although SDS-
PAGE and Western immunoblotting is a standard method to document
particular proteins using reducing conditions, under non-reducing
conditions as was used in our experiments, sequencing would have
further helped to prove the protein speciﬁcity; however, this was
not done.
2.3. Phosphatase activity of SHP-1 isoforms
We then investigated the SHP-1 activity of the three different protein
isoforms. Wild-type (wt), exon 3-deleted, exons 3- and 4-deleted, and
phosphatase dead (C453S) SHP-1 constructs were cloned into pGEX-
4T-2 glutathione S-transferase (GST) expression vectors and the resulting
GST-fusion proteins puriﬁed. Using these fusion proteins to evaluate the
phosphatase activity of our SHP-1 constructs indicated no signiﬁcant
differences (data not shown). This was perplexing as we anticipated
that the construct lacking exons 3 and 4 would have increased phospha-
tase activity due to a loss of autoinhibition of the enzymatic activity and
previous publications that supported this [23,29–35]. Indeed, murine
SHP-1 proteins lacking the N-SH2 domain have demonstrated a 5-fold
increase in phosphatase activity when compared to wild-type SHP-1
[17,23]. These anomalies led us to believe that the low level of exon 3-
deleted GST fusion protein and steric interference by the GST may pre-
clude accurate testing of the activity of the SHP-1 isoforms. We therefore
assessed the phosphatase activity of SHP-1 constructs using thrombin-
cleaved-GST SHP-1 proteins.
Thrombin-cleaved-GST SHP-1 proteins were immunoprecipitated
using monoclonal anti-SHP-1 antibodies. We aimed at achieving an
equal protein distribution to ensure that concentrations were not a
factor when assessing differences in phosphatase activity. In this
experiment, we were not able to obtain enough exon 3-deleted protein
to accurately measure phosphatase activity compared to wild-type SHP-
1. However, we were able to obtain adequate protein for wild-type and
exons 3- and 4-deleted SHP-1 and observed a 3-fold increase in phospha-
tase activity of SHP-1 protein lacking exons 3 and 4 when compared to
wild-type SHP-1 protein (Fig. 3, these results were statistically signiﬁcant
(p b 0.05)). Thus, as inmurine SHP-1 [17,23], humanSHP-1when lacking
the N-SH2 domain has greatly increased phosphatase activity.
2.4. Phosphatase activity of SHP-1 variants expressed in HEK 293 cells
To further examine the phosphatase activity of SHP-1 variants
under more physiologic conditions, we used transfection of each
SHP-1 cDNA having an Xpress tag into HEK 293 cells and then anti-
Xpress immunoprecipitation of the expressed proteins. The transfectants
were divided equally for subsequent protein expression analysis and
phosphatase activity assessment. Western immunoblotting using
monoclonal anti-SHP-1 allowed the detection of the SHP-1 proteins
corresponding to the sizes predicted by the multiple mRNAtranscripts (full-length wild-type & C453S: 68 kDa; exon 3 deletion:
63 kDa; exons 3 and 4 deletion: 56 kDa) (Fig. 4A). SHP-1 protein
constructs were demonstrating differential expression levels when
transfected into HEK 293 cells. We therefore used a densitometry
analysis to empirically ensure equal distribution of cells for transfec-
tion (Fig. 4A). We consistently observed reduced expression of
the exon 3-deleted SHP-1 protein construct in HEK 293 transfects
(Figs. 4A and B). However, we were able to obtain enough protein
expression of exon 3-deleted SHP-1 to demonstrate that it has phos-
phatase activity similar to wild-type SHP-1 (Fig. 4C). Our results, as
in Fig. 3B, again showed that the phosphatase activity of exons 3-
and 4-deleted SHP-1 protein was approximately 4-fold higher when
compared to wild-type SHP-1 proteins (Figs. 4A and B). These results
were statistically signiﬁcant (p b 0.05). Taken together, results from
Figs. 3 and 4 conﬁrm the results of Martin et al., who found that
murine SHP-1 lacking the N-SH2 domain has a 5-fold higher speciﬁc
phosphatase activity than wild-type when transfected in COS-1 cells
[17,23].
In addition to truncation of the N-SH2 domain, it is possible that
posttranslational modiﬁcations may have inﬂuenced the function/
activity of these proteins. Although both tyrosine and serine phosphory-
lation of SHP-1 have been proposed to affect its activity and function
[36–38], this work was done in hematopoietic cells and these phosphor-
ylation events appear to occur only in the C-terminal region of SHP-1;
thus, may not play a role in our studies, although we did not investigate
phosphorylation.2.5. Differential protein binding activity of SHP-1 variants
We next examined the protein binding partners for the different
SHP-1 proteins. Protein–protein interactions are responsible for
regulating various signaling pathways that drive normal cellular
functions. Improper interactions may disrupt signaling pathways
and promote neoplastic transformations. Our SHP-1 variant protein
constructs exhibited structural alteration (in particular the partial
or complete absence of the N-terminal SH2 binding domain) which
may lead to novel and uncharacterized protein–protein interactions.
We measured protein–protein interactions of wild-type, exon 3-
deleted, exons 3- and 4-deleted and C453S SHP-1 constructs in KiT
225 cells (lacking endogenous SHP-1 (18)) using 35S-biosynthetic la-
belling and a GST-fusion protein pull-down assay. Using Western
blotting (Fig. 5A) to ensure that the same amount of each GST-
fusion protein was used in each pull-down, we incubated this
amount with lysate from the biosynthetically labeled KiT 225
cells to compare 35S-proteins pulled down by each GST-fusion
construct.
When compared to wild-type SHP-1, exon 3-deleted SHP-1 dem-
onstrated several additional protein interactions that were absent in
wtSHP-1 (Fig. 5). We observed a prominent ~90 kDa band as well as
a large amount of protein at ~30 kDa that exclusively interacted with
exon 3-deleted SHP-1. It is possible that these additional proteins are
ones involved in causing the unstable nature in the expression of this
protein in vitro; perhaps involved in increasing degradation and/or
ubiquitination. Exon 3- and 4-deleted SHP-1 proteins exhibited sig-
niﬁcantly reduced interactions, consistent with the role of the entire
N-SH2 domain as being responsible for the interaction of SHP-1 with
phosphotyrosine-containing proteins [30]. However, a weak protein
of ~38 kDa was observed with exon 3- and 4-deleted SHP-1. This
protein is likely the adaptor protein CrkL which we have previously
shown binds to SHP-1 via its SH3 domains to PxxP motifs present
within the C-SH2 and PTP domains of SHP-1 [14]. As expected, dom-
inant negative C453S SHP-1 exhibited a comparable array of protein
partners as with wild-type SHP-1 (Fig. 5B) as this construct has been
shown to act as a substrate trap due to its lack of phosphatase
activity.
Fig. 3. Phosphatase activity of variant SHP-1 proteins. (A) Western blot of thrombin-cleaved-GST SHP-1 proteins. Thrombin-cleaved SHP-1 was immunoprecipitated using monoclonal
anti-SHP-1 speciﬁc for the C-terminus and Western blotted under non-reducing conditions. (B) Densitometry analysis of the variant SHP-1 proteins as well as the C453S phosphatase
dead control is shown as well as (C) phosphatase activity using a malachite green assay.
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We have identiﬁed multiple, novel SHP-1 transcripts in epithelial
cancer cells. The transcripts we have identiﬁed use either promoter 1
or promoter 2 to generate full-length wild-type SHP-1 or truncated
transcripts lacking either exon 3 or both exons 3 and 4. In addition we
have shown that a noncoding transcript is generated by either promoter
where intron 2 is retained resulting in a frame shift and stop codon, as
we previously have shown for SHP-1 transcripts in hematopoietic cells
[18]. This is theﬁrst evidence that SHP-1 is generated by both promoters
in epithelial cells. We also have provided data that proteins corre-
sponding to each of the open-reading frame transcripts are produced
in epithelial cancer cell lines. Furthermore, we show that these truncated
proteins have differential phosphatase activity and have different protein
binding partners.
Previously, only promoter 1 was shown to be active in production of
SHP-1 transcripts of full-length or lacking exon 3 or exons 3 and 4, and
SHP-1 proteins were only found for the full-length transcript [6]. Our
work indicates that both promoters are active in epithelial cells and pro-
teins of 68 kDa, 63 kDa and 56 kDa, corresponding to each of the open
reading frame transcripts, can be detected in epithelial cancer cells. As
truncated SHP-1 proteins were identiﬁed in both MCF-7 and SK-BR-3
breast cancer cell lines, these proteinsmay have a role in tumorigenesis,
as previously suggested for truncated SHP-1 proteins that have been
identiﬁed in hematopoietic cells [18,39,40]. Recently, it has been
shown that SHP-1 expression is related to the proliferation of breast
cancer cells [28]. Thus, the role of truncated SHP-1 in epithelial cancers
requires further study to determine if these proteins have different
functional outcomes in certain cancers. This is an important questionas we demonstrated a differential expression of the truncated proteins
in colon, breast and other cancer cells (Fig. 2D). Also, these proteins
bind different substrates and have differential phosphatase activity;
thus, may play a role in carcinogenesis.
This study is the ﬁrst to show promoter 2 usage in epithelial cells.
Hyper-methylation and transcriptional inactivation of promoter 2
have been observed in several epithelial cells [40]. However, in diseases
such as psoriasis and various skin lesions such as squamous cell carcino-
ma, promoter 2 is hypo-methylated and elevated SHP-1 expression has
been observed, suggesting that promoter 1 and 2 utilization is common
in epithelial cells [41]. Hypo-methylation of the SHP-1 promoter 2
region has also been observed with the onset of several hematopoietic
tumors such as CML and several leukemias, indicating that promoter 2
may be easily susceptible to modiﬁcations, in particular hypo-
methylation. The elevation or reduction of SHP-1 expression may be
a result of a cell speciﬁc characteristic.
Banville et al., [6] suggested that signiﬁcant structural alterations
may lead to functional changes of SHP-1 proteins. Speciﬁcally, abnormal
phosphatase activity and uncharacteristic protein–protein interactions
have been hypothesized as a consequence of SHP-1 structural alter-
ations [6,39]. In fact, murine SHP-1 proteins lacking the N-SH2 domain
have demonstrated a 5-fold increase in phosphatase activitywhen com-
pared to wild-type SHP-1 [27,30]. As with murine SHP-1, in our studies,
SHP-1 variants lacking exons 3 and 4 (the N-SH2 domain) demonstrat-
ed elevated phosphatase activity in vitro. In addition, SHP-1 variants
lacking exon 3 also exhibited novel protein–protein interactions.
These results suggest that structural alterations of SHP-1 may lead to
loss of regulatory function of normal signaling pathways, and this
could lead to a pathologic condition such as tumorigenesis [40].
Fig. 4. Transfection/expression of SHP-1 variant cDNAs. (A) Transfectants expressing Xpress were immunoprecipitated using anti-Xpress and Western immunoblotted using anti-SHP-1
under non-reducing conditions. Jurkat cells served as a positive control and anti-Xpress alone bound to Protein G-Sepharose and empty vector served as negative controls. Densitometry
analysis is also shown. (B) Repeat of (A) but also showing phosphatase activity of isolated proteins. (C) Isolation and characterization of the exon 3-deleted protein showing Western
immunoblot results and phosphatase activity.
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4.1. Cells
The Jurkat human T cell leukemia cell line was obtained from
American Type Culture Collection (E6-1, ATCC #TIB-152), KiT 225human acute T-cell leukemia-derived cells, lacking SHP-1 protein
[18], were a gift from Dr. G. B. Mills (MD Anderson Cancer Center,
Houston, TX, USA), SK-BR-3 mammary gland epithelial adenocarci-
noma cells were obtained from ATCC (ATCC#: HTB-30), human
embryonic kidney (HEK) 293 epithelial cells were obtained from
the NIH AIDS Research and Reference Reagent Program (#18-036).
Fig. 5. Protein binding partners for variant SHP-1 proteins. (A) GST fusion proteins used in pull-down on Western immunoblot showing expected sizes and equal levels of GST-fusion
proteins. (B) KiT 225 cells were incubated with 35S-methionine and 35S-cysteine, lysed and the biosynthetically radiolabeled proteins pulled down using the GST-fusion proteins. GST
alone was a negative control. Molecular size standards are indicated on the right while arrows on the left indicate the 38 kDa protein (likely CrkL) that is bound by the exon 3-4 deleted
protein lacking the N-SH2 domain and the 30 kDa protein that is a major protein bound to the exon 3-deleted variant SHP-1.
497S. Evren et al. / Genomics 102 (2013) 491–499Additional human epithelial cell lines used in these studies include were
from ATCC: Colo 205 (#CCL-222), MCF-7 (#HTB-22), A431 (#CRL-1555),
MD-MB-231 (MB 231, #HTB-26) and MCF-10A (#CRL-10317).
4.2. Antibodies, Western immunoblots, immunoprecipitation and
membrane stripping
Mouse monoclonal anti-SHP-1 antibody recognizing the C-terminus
(BD Biosciences, Mississauga, Ontario, cat # 611334) or a rabbit poly-
clonal anti-SHP-1 #170 (a generous gift from Dr. K. Siminovitch)
were used at 1:1000 dilution. Cells were lysed using a radioimmune
precipitation assay (RIPA) buffer, resolved by sodium dodecyl sulfate-
acrylamide gel electrophoresis (SDS-PAGE), and transferred onto
nitrocellulose membranes (Amersham Pharmacia Biotech Inc.)[18,42].
Western blotting was performed as previously [14,18] using primary
monoclonal anti-SHP-1 followed by goat-anti-mouse horseradish
peroxidase (HRP) used as a secondary antibody. Protein bands
were visualized using enhanced chemiluminescence (ECL) Western
blotting detection reagents (Amersham Pharmacia Biotech Inc.).
Immunoprecipitation was done as previously described [14]. Anti-
body complexes were ﬁrst prepared by initial binding to Protein G
PLUS-Agarose beads (Santa Cruz Biotechnology, Inc.) Prepared anti-
body complexes were added to cell lysates or GST thrombin-cleavedSHP-1 fusion proteins to mediate immunoprecipitation. Immune com-
plexes were used in Western blotting and/or subjected to phosphatase
assays.
For immunoprecipitation of endogenous SHP-1 proteins, we used a
slightly different method that we have described previously [42]. Fifty
million cells were lysed with RIPA and the lysate mixed with Protein
A-Sepharose beads (GE Healthcare Life Sciences Inc., Baie D'Urfe,
Quebec) which had been pre-bound, ﬁrst with rabbit-anti-mouse Ig
(RAM;Western Blotting Enterprises, Oakville, ON) followed by bind-
ing to RAM with monoclonal anti-SHP-1 (or monoclonal anti-Xpress
(Invitrogen™, Carlsbad, CA)). Non-reducing conditions were used
for SDS-PAGE when investigating SHP-1 proteins to eliminate any
interference from the heavy chains of the immunoprecipitating anti-
body allowing for clear identiﬁcation of SHP-1 proteins of 63 kDa
and 56 kDa.
4.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
and sequencing
mRNA fromvarious cell lineswas isolated using theQuickPrepMicro
mRNA Puriﬁcation Kit (Amersham Pharmacia Biotech Inc.) and cDNA
was synthesized using First-Strand cDNA Synthesis Kit (Amersham
Pharmacia Biotech Inc.) Human SHP-1 cDNAs were ampliﬁed using
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ggaagcccc cag gat g-3′); epithelial forward (EF) primer (5′-gag gagg
aagtggct gat tac-3′); reverse primer 3R speciﬁc to exon 5 (5′-cacat
caaggtcatgtgc gag-3′). The forward and reverse primer pairs used were
speciﬁc for the ampliﬁcation of the N-terminus SH2 domain region
spanning exon 1 or exon 2 to exon 5 (Fig. 1).
5. SHP-1 cDNA construct synthesis and mutagenesis
PCR products of multiple SHP-1 transcripts were cloned into pGEM-T
Easy vectors. Full-length human SHP-1 was cloned using PCR (wtSHP-1
forward primer: 5′-GATCAGGAATTCCCAGGATGGTGAGGT-3′) based on
previously published sequence from normal primary peripheral blood
mononuclear cells [18]. Forward primers were designed that would an-
neal at the 5′ EcoRI site within the pGEM-T Easy vector covering the N-
terminal sequence (ﬁrst exon) of the full length SHP-1 sequence. The pro-
moter 2/exon 3 deletion forward primer sequence (5′-GATCAGGAATT
CCCAGGATGGTGAGGGTGGGGGATCAG-3′) was designed by incorporat-
ing the 5′ ﬂanking EcoRI site, exon 2 (MVR) and 5′ sequences of exon 4.
The promoter 1/exon 3 and 4 deletion forward primer sequence (5′-
CAGGAATTCCCTACAGAGAGATGCTGTCCCGTGGGTGGTACCATGGCCACAT
GTCT-3′) incorporates the 5′ ﬂanking EcoRI site, exon 1 (MLSRG) and 5′
sequences of exon5. A reverse primer anneals at the SHP-1C-terminal se-
quences (5′-CCACCTGAGGACAGCACCGCT-3′). PCR products were cloned
into the pGEX-4T-2 glutathione S-transferase (GST) expression vector
(Amersham Pharmacia Biotech Inc.) and pcDNA3.1/HisAmammalian ex-
pression vector (Invitrogen) at their EcoRI sites. Full-length SHP-1/C453S
mutant was generated by oligonucleotide-directed mutagenesis in the
SHP-1 phosphatase recognition site for ATP; Cys/Ser (Cys→ Ser). Specif-
ically, SHP-1/C453S was made using a forward primer: 5′-CATCGTGCAC
TCCAGCGCCGGCATCGGCCGCACAGGC-3′. The PCR products were cloned
into the pGEX-4T-2 GST expression vector at the corresponding
restriction sites located downstream from GST. The SHP-1/C453S cDNA
insert was subcloned into the EcoRI and XhoI sites of pcDNA3.1/HisA
mammalian expression vector for subsequent transfection into cells.
5.1. Expression, puriﬁcation and thrombin cleavage of GST fusion proteins
Wild-type, exon 3 deletion, exons 3 and 4 deletion and C453S
SHP-1 cDNA constructs were cloned into pGEX-4T-2. GST-SHP-1
fusion proteins were ampliﬁed in Escherichia coli strain BL21 (DE3;
Stratagene, La Jolla, CA) and induced with 0.4 mM isopropyl-β-D-
thiogalactopyranoside (IPTG). GST fusion proteins were puriﬁed
using 50% glutathione sepharose 4B beads. A thrombin cleavage
site (Leu–Val–Pro–Arg–Gly–Ser) was present in all pGEX-4T-2 GST
expression vectors. GST fusion protein–glutathione sepharose 4B
beads complexes were treated with thrombin protease (Amersham
Pharmacia Biotech Inc.). Reaction buffers were collected for subsequent
immunoprecipitation assay.
5.2. Malachite green phosphatase assay
Phosphatase assays were performed on thrombin-cleaved GST-
fusion SHP-1 proteins (wild-type and variants), TDL monoclonal anti-
SHP-1 immunoprecipitates of GST thrombin-cleaved SHP-1 proteins
(wild-type and variants) and HEK 293 transfectants bound on Protein
G-Agarose beads using a Malachite green phosphatase assay kit
(Upstate Cell Signaling Solutions Catalog #17-125). Proteins bound
on glutathione or protein G-agarose beads were washed with Malachite
green assay buffer. Phosphopeptides (RRLIEDAEpYAARG) were added
and incubated with Malachite green detection reagent (99% Malachite
Green (Solution A) Upstate Cell Signaling Solutions Catalog #20-105; 1%
Malachite Green Additive (Solution B) Upstate Cell Signaling Solutions
Catalog #20-103). Phosphatase activities were measured by SpectraMax
Plus384 and SOFTmax®PRO reader software. Sample absorbance readings
were converted to phosphate concentration based on the Beer's Law.5.3. Transfection
SHP-1 cDNA constructs cloned into pcDNA3.1/HisA mammalian
expression vectors and were transfected into HEK 293 epithelial cells
using the Effectene Transfection Kit (QIAGEN). Transfected cells were
cultured in complete medium at 37 °C under 5% CO2 for 48 h before
harvesting.
5.4. Metabolic 35S-Labelling/GST pull-down assay
KiT 225 cells were labeled with 2 mCi of 35S-Cys and 35S-Met and
then lysed with RIPA buffer. To perform the GST pull-down assay, pre-
cleared lysates were added to glutathione sepharose 4B beads bound
GST alone (control) and GST fusion proteins. GST pulled-down proteins
were separated by SDS-PAGE on a polyacrylamide gel. The gels were
ﬁxed with 7% acetic acid and soaked in Amplify NAMP 100 (Amersham
Pharmacia Biotech Inc.) ﬂuorographic enhancer solution. Gels were
dried using a BioRadModel 583 gel dryer at 80 °C and radioﬂuorescence
was captured on Kodak BioMax MR ﬁlm.
Grant support
S. Wan is a recipient of the Ontario Women's Health Scholar Award.
Acknowledgments
The authors thank Yulia Katsman for technical assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2013.10.001.
References
[1] T.R. Burke, Z.Y. Jr Zhang, Protein–tyrosine phosphatases: structure, mechanism, and
inhibitor discovery, Biopolymers 47 (1998) 225–241.
[2] H. Gu, B.G. Neel, The “gab” in signal transduction, Trends Cell Biol. 13 (2003)
122–130.
[3] A. Ullrich, J. Schlessinger, Signal transduction by receptors with tyrosine kinase
activity, Cell 61 (1990) 203–212.
[4] B.G. Neel, N.K. Tonk, Protein tyrosine phosphatases in signal transduction, Curr.
Opin. Cell Biol. 9 (1997) 193–204.
[5] D. Pei, U. Lorenz, U. Klingmüller, B.G. Neel, C.T. Walsh, Intramolecular regulation of
protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains,
Biochemistry 33 (1994) 15483–15493.
[6] D. Banville, R. Stocco, S.H. Shen, Human protein tyrosine phosphatase 1C (PTPN6)
gene structure: alternate promoter usage and exon skipping generate multiple
transcripts, Genomics 27 (1995) 165–173.
[7] S.C. Mok, T.T. Kwok, R.S. Berkowitz, A.J. Barrett, F.W. Tsui, Overexpression of the
protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial
ovarian cancer, Gynecol. Oncol. 57 (1995) 299–303.
[8] H.W. Tsui, K. Hasselblatt, A. Martin, S.C. Mok, F.W. Tsui, Molecular mechanisms
underlying SHP-1 gene expression, Eur. J. Biochem. 269 (2002) 3057–3064.
[9] J. Plutzky, B.G. Neel, R.D. Rosenberg, R.L. Eddy, M.G. Byers, S. Jani-Sait, T.B. Shows,
Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6),
Genomics 13 (1992) 869–872.
[10] M. Matsushita, N. Tsuchiya, T. Oka, A. Yamane, K. Tokunaga, New variations of
human SHP-1, Immunogenet. 49 (1999) 577–579.
[11] S.H. Shen, L. Bastien, B.I. Posner, P. Chretien, A protein–tyrosine phosphatase with
sequence similarity to the SH2 domain of the protein–tyrosine kinases, Nature
352 (1991) 736–739.
[12] T. Pawson, G.D. Gish, SH2 and SH3 domains: from structure to function, Cell 71
(1992) 359–362.
[13] J. Plutzky, B.G. Neel, R.D. Rosenberg, Isolation of a src homology 2-containing
tyrosine phosphatase, Proc. Natl. Acad. Sci. 89 (1992) 1123–1127.
[14] S. Evren, X.Z. Ma, D. Sakic, D.R. Branch, SHP-1 protein tyrosinephosphatase
associates with the adaptor protein CrkL, Exp. Hematol. 40 (2012) 1055–1059.
[15] K.A. Siminovitch, B.G. Neel, Regulation of B cell signal transduction by SH2 contain-
ing protein–tyrosine phosphatases, Semin. Immunol. 10 (1998) 329–347.
[16] J.S. Bignon, K.A. Siminovitch, Identiﬁcation of PTP1C mutation as the genetic defect
in motheaten and viable motheaten mice: a step toward deﬁning the roles of pro-
tein tyrosine phosphatases in the regulation of hemopoietic cell differentiation
and function, Clin. Immunol. Immunopathol. 73 (1994) 168–179.
499S. Evren et al. / Genomics 102 (2013) 491–499[17] A. Martin, H.W. Tsui, F.W. Tsui, SHP-1 variant proteins are absent inmotheatenmice
despite presence of splice variant transcripts with open reading frames, Mol.
Immunol. 36 (1999) 1029–1041.
[18] X.Z. Ma, T. Jin, D. Sakac, S. Fahim, X. Zhang, Y. Katsman, M. Bali, D.R. Branch, Abnor-
mal splicing of SHP-1 protein tyrosine phosphatase in human T cells: implications
for lymphomagenesis, Exp. Hematol. 31 (2003) 131–142.
[19] L.D. Shultz, P.A. Schweitzer, T.V. Rajan, T. Yi, J.N. Ihle, R.J. Matthews, M.L. Thomas,
D.R. Beier, Mutations at the murine motheaten locus are within the hematopoietic
cell protein–tyrosine phosphatase (Hcph) gene, Cell 73 (1993) 1445–1454.
[20] B.G. Neel, Structure and function of SH2-domain containing phosphatase, Semin.
Cell Biol. 4 (1993) 419–432.
[21] C. Wu, M. Sun, L. Liu, G.W. Zhou, The function of the protein tyrosine phosphatase
SHP-1 in cancer, Gene 306 (2003) 1–12.
[22] B. Bruecher-Encke, J.D. Grifﬁn, B.G. Neel, U. Lorenz, Role of the tyrosine phosphatase
SHP-1 in K562 cell differentiation, Leukemia 15 (2001) 1424–1432.
[23] A.Martin, H.W. Tsui, M.J. Shulman, D. Isenman, F.W. Tsui, Murine SHP splice variants
with altered Src homology 2 (SH2) domains. Implications for the SH2-mediated
intramolecular regulation of SHP-1, J. Biol. Chem. 274 (1999) 21725–21734.
[24] K.A. Siminovitch, A.M. Lamhonwah, A.K. Somani, R. Cardiff, G.B. Mills, Involvement
of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor sig-
naling, proliferation and transformation, Curr. Top. Microbiol. Immunol. 246 (1999)
291–297.
[25] F.W. Tsui, A. Martin, J. Wang, H.W. Tsui, Investigations into the regulation and function
of the SH2 domain-containing protein–tyrosine phosphatase, SHP-1, Immunol. Res. 35
(2006) 127–136.
[26] P.D. Zapata, R.M. Ropero, A.M. Valencia, L. Buscail, J.I. Lopez, R.M. Martin-Orozco, J.C.
Prieto, J. Angulo, C. Susini, P. Lopez-Ruiz, B. Colas, Autocrine regulation of human
prostate carcinoma cell proliferation by somatostatin through the modulation
of the SH2 domain containing protein tyrosine phosphatase (SHP)-1, J. Clin.
Endocrinol. Metab. 87 (2002) 915–926.
[27] S.S. Yip, A.J. Crew, J.M. Gee, R. Hui, R.W. Blamey, J.F. Robertson, R.I. Nicholson, R.L.
Sutherland, R.J. Daly, Up-regulation of the protein tyrosine phosphatase SHP-1 in
human breast cancer and correlation with GRB2 expression, Int. J. Cancer 88
(2000) 363–368.
[28] S. Amin, A. Kuman, L. Nilchi, K. Wright, M. Kozlowski, Breast cancer cells proliferation
is regulated by tyrosine phosphatase SHP1 through c-jun N-terminal kinase and
cooperative induction of RFX-1 and AP-4 transcription factors, Mol. Cancer Res. 9
(2011) 1112–1125.
[29] M. Nehls, M. Schorpp, T. Boehm, An intragenic deletion in the human PTPN6 gene
affects transcriptional activity, Hum. Genet. 95 (1995) 713–715.[30] D. Pei, J. Wang, C.T. Walsh, Differential functions of the two Src homology 2
domains in protein tyrosine phosphatase SH-PTP1, Proc. Natl. Acad. Sci. 93
(1996) 1141–1145.
[31] R. Townley, S.H. Shen, D. Banville, C. Ramachandran, Inhibition of the activity of
protein tyrosine phosphate 1C by its SH2 domains, Biochemistry 32 (1993)
13414–13418.
[32] S. Sugimoto, T.J. Wandless, S.E. Shoelson, B.G. Neel, C.T. Wash, Activation of the
SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-
containing peptides derived from insulin receptor substrate-1, J. Biol. Chem. 269
(1994) 13614–13622.
[33] J. Yang, L. Liu, D. He, X. Song, X. Liang, Z.J. Zhao, G.W. Zhou, Crystal structure of
human protein tyrosine phosphatase SHP-1, J. Biol. Chem. 278 (2003) 6516–6520.
[34] W.Wang, L. Liu, X. Song, Y. Mo, C. Komma, H.D. Bellamy, Z.J. Zhao, G.W. Zhao, Crystal
structure of human protein tyrosine phosphatase SHP-1 in the open conformation, J.
Cell Biochem. 112 (2011) 2062–2071.
[35] Q. Zhang, P.N. Raghunath, E. Vonderheid, N. Odum, M.A. Wasik, Lack of
phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma
cells results from methylation of the SHP-1 promoter, Am. J. Pathol. 157 (4)
(2000) 1137–1146.
[36] U. Lorenz, K.S. Ravichandran, D. Pei, C.T. Walsh, S.J. Burakoff, B.G. Neel,
Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase
SH-PTP1 in murine T cells, Mol. Cell. Biol. 14 (3) (1994) 1824–1834.
[37] M.L. Jones, J.D. Craik, J.M. Gibbins, A.W. Poole, Regulation of SHP-1 tyrosine
phosphatase in human platelets by serine phosphorylation at its C terminus,
J. Biol. Chem. 279 (39) (2004) 40475–40483.
[38] L. Yin, M.J. Kruhlak, H. Jian-Jiang, S. Shaw, Rapid TCR-mediated SHP-1S591 phos-
phorylation regulates SHP-1 cellular localization and phosphatase activity, J. Leukoc.
Biol. 82 (3) (2007) 742–751.
[39] Y.J. Jin, C.L. Yu, S.J. Burakoff, Human 70-kDa SHP-1 L differs from 68-kDa SHP-1
in its C-terminal structure and catalytic activity, J. Biol. Chem. 274 (1999)
28301–28307.
[40] C. Vinayanuwattikun, V. Sriuranpong, S. Tanasanvimon, P. Chantranuwat, A.
Mutirangura, Epithelial-speciﬁc methylation marker: a potential plasma bio-
marker in advanced non-small cell lung cancer, J. Thorac. Oncol. 6 (11)
(2011) 1818–1825.
[41] K. Ruchusatsawat, J. Wongpiyabovorn, S. Shuangshoti, N. Hirankarn, A. Mutirangura,
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in
psoriasis, J. Mol. Med. 84 (2) (2006) 175–182.
[42] D.R. Branch, G.B. Mills, pp60c-Src expression is induced by activation of normal.
human T lymphocytes, J. Immunol. 154 (8) (1995) 3678–3685.
